Previous studies have shown that interferon-gamma (IFN-γ) is a proinflammatory cytokine that contributes to the pathogenesis of Guillain-Barré syndrome and its animal model, experimental autoimmune neuritis (EAN). Treatments with anti-IFN-γ antibodies improve clinical outcome in GBS patients and EAN animals and administration of IFN-γ markedly worsens EAN. Paradoxically, the mice deficient in IFN-γ remain susceptible to experimental autoimmune encephalomyelitis, an analogous disease in the central nervous system. These observations raise a question whether IFN-γ might be protective in autoimmune demyelinating diseases. To clarify the role of IFN-γ in the pathogenesis of autoimmune demyelinating diseases, we used P0 protein peptide 180-199 to induce EAN in IFN-γ knockout (KO) mice. After the acute phase of EAN, the clinical signs of IFN-γ KO mice were significantly more severe than those of wild type (WT) controls. After antigenic stimulation, the proliferation of splenic mononuclear cells was significantly higher in IFN-γ KO than in WT mice with EAN. At the peak of EAN, the proportion of interleukin (IL)-17A expressing cells in cauda equina (CE) infiltrating cells, and the levels of IL-17A in sera were elevated in IFN-γ KO mice when compared with their WT counterparts. The proportions of major histocompatibility complex (MHC) II, macrosialin, and IL-12/IL-23p40 expressing cells, relative to total CE infiltrating cells were correspondingly higher in IFN-γ KO than in WT mice with EAN. However, IFN-γ deficiency reduced the production of NO by cultured macrophages in response to proinflammatory stimuli and induced a systemic Th2-oriented immune response. In conclusion, IFN-γ deficiency exacerbates EAN via upregulating Th17 cells despite a mitigated systemic Th1 immune response.
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Introduction
Guillain-Barré syndrome (GBS) is an inflammatory demyelinating disease of the peripheral nervous system (PNS) in humans. As a heterogeneous disease entity, GBS is currently defined as an organ specific immune mediated disorder resulting from a synergistic interaction between cellular and humoral immune responses to incompletely characterized antigens in the PNS (van Doorn et al., 2008; Zhang et al., 2010) . The exact pathogenesis of GBS remains largely unknown. Experimental autoimmune neuritis (EAN) shares many clinical, histopathological, and electrophysiological features with acute inflammatory demyelinating polyneuropathy, a common clinical subtype of GBS and is therefore used as an animal model to explore the pathogenesis of GBS. Pathologically, EAN is characterized by breakdown of the blood-nerve barrier, robust accumulation of reactive T cells and macrophages in the PNS and demyelination of peripheral nerves (Zhang et al., 2008) .
As a typical marker for a Th1 response, interferon-gamma (IFN-γ) is produced by T helper (Th)1 cells. IFN-γ exerts its proinflammatory role by activating endothelial cells, macrophages and T cells. IFN-γ increases the expression of main histocompatibility complex (MHC) II thereby enhancing the antigen presenting capacity of macrophages. The potent proinflammatory activities of IFN-γ combined with its inhibitory potential for the development of Th2 cells make IFN-γ a central mediator of Th1 mediated autoimmune disorders. In addition to activation of macrophages and induction of MHC expression, IFN-γ induces the differentiation of T cells to a Th1 phenotype, B cell class Journal of Neuroimmunology 246 (2012) 18-26 
